Clinical trial · Interventional
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant
NCT01827579CI-TRIAL-00059792ICATcompletedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Haematological Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CD25/71 allodepleted donor T-cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CD25/71 allodepleted donor T-cells
- description
- CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
- interventionNames
- Biological: CD25/71 allodepleted donor T-cells
- type
- NO_INTERVENTION
- label
- Control (normal HSCT)
- description
- Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
Primary outcomes (1)
- measure
- Circulating CD3+ve T cell count at 4 months post-SCT
- timeFrame
- 4 months post transplant
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥16 years * Underlying haematological malignancy * Planned allogeneic peripheral blood stem cell transplantation from a 10/10 or 9/10 HLA matched unrelated donor, using an Alemtuzumab-based conditioning protocol * Written Informed consent Exclusion Criteria: * Life expectancy \< 6 weeks * Female patients who are pregnant and lactating * Patients who are serologically positive for Hepatitis B, C or HIV pre-SCT
References
Publications (0)
Data not yet available
No reference posted for this study.